Xilio Therapeutics Appoints Cheryl Blanchard to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy XLO?
Xilio Therapeutics announced the appointment of Cheryl Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XLO
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xilio Therapeutics Appoints Cheryl R. Blanchard to Board
- Board Appointment: Xilio Therapeutics has appointed Dr. Cheryl R. Blanchard to its board, bringing over 30 years of leadership experience in biopharmaceuticals, which is expected to enhance the company's expertise in advancing next-generation immuno-oncology therapies toward clinical application.
- Executive Transition: Christina Rossi stepped down from the board effective April 15, 2026, with Xilio expressing gratitude for her contributions over the past five years, indicating ongoing adjustments and optimizations within the executive team.
- Technological Potential: Dr. Blanchard highlighted that Xilio's masking technology has the potential to significantly improve treatment outcomes for cancer patients by delivering highly effective and low-toxicity multi-specific immunotherapies, showcasing the company's strategic advantage in innovative drug development.
- Industry Influence: With her previous executive roles, particularly at Anika Therapeutics, Dr. Blanchard is poised to enhance Xilio's market competitiveness and strategic direction, leveraging her extensive experience in the life sciences sector.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: On April 1, 2026, Xilio Therapeutics granted 3,257 non-qualified stock options to two new employees at an exercise price of $8.48 per share, equal to the closing price that day, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Vesting Arrangement: The stock options will vest 25% after the first year of employment, with the remaining 75% vesting in 36 equal monthly installments, ensuring continued employee contribution during their tenure with the company.
- Incentive Plan Context: This grant aligns with Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, designed to attract new employees in accordance with Nasdaq Listing Rule 5635(c)(4), thereby improving the overall talent quality within the company.
- Strategic Company Goals: Xilio Therapeutics focuses on developing immuno-oncology therapies without systemic side effects, leveraging proprietary masking technology to optimize anti-tumor activity, thereby enhancing treatment outcomes for cancer patients and showcasing the company's innovative potential in the biotechnology sector.
See More
XILIO THERAPEUTICS INC Reports Q4 Net Income of $10.36 Million
Company Overview: The article discusses the financial performance of a company named X, specifically focusing on its net income for the fourth quarter.
Financial Results: X reported a net income of USD 10.36 million for Q4, indicating a significant financial achievement for the period.
See More
XILIO THERAPEUTICS INC - FUNDING NOW SECURED UNTIL THE END OF 2027
Therapeutics in Cash Runway: The company has extended its cash runway through the end of 2027, indicating financial stability for ongoing projects.
Future Plans: This extension allows for continued investment in therapeutic development and potential new initiatives without immediate financial pressure.
See More
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
- Reverse Stock Split Plan: Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, aimed at increasing the per-share market price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Capital Adjustment Impact: The reverse split will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million, with trading expected to commence on a split-adjusted basis on March 16, 2026, enhancing per-share value to attract investors.
- Market Reaction: Following the reverse split announcement, XLO shares fell 16.48% in premarket trading to $0.451, indicating market concerns regarding the company's current stock price and future outlook, which may affect investor confidence.
- Compliance Objective: By implementing the reverse stock split, Xilio aims to restore compliance with Nasdaq, ensuring the company can continue trading in the public market and avoid delisting risks due to low stock prices.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Xilio Therapeutics granted 50,050 non-qualified stock options to two new employees, with an exercise price of $0.5283 per share, reflecting the company's proactive approach to talent acquisition.
- Option Structure: Each stock option has a ten-year term, with 25% of shares vesting after the first year and the remaining 75% vesting in 36 equal monthly installments, designed to incentivize long-term employee retention and enhance company stability.
- Incentive Plan Context: The stock options are granted under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4) to attract new talent, demonstrating the company's commitment to human resources.
- Strategic Company Goals: Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients, leveraging proprietary technology to advance novel therapeutic molecules, showcasing its innovative capabilities in the biotechnology sector.
See More
Xilio Therapeutics Appoints Cheryl R. Blanchard to Board
- Board Appointment: Xilio Therapeutics has appointed Dr. Cheryl R. Blanchard to its board, bringing over 30 years of leadership experience in biopharmaceuticals, which is expected to enhance the company's expertise in advancing next-generation immuno-oncology therapies toward clinical application.
- Executive Transition: Christina Rossi stepped down from the board effective April 15, 2026, with Xilio expressing gratitude for her contributions over the past five years, indicating ongoing adjustments and optimizations within the executive team.
- Technological Potential: Dr. Blanchard highlighted that Xilio's masking technology has the potential to significantly improve treatment outcomes for cancer patients by delivering highly effective and low-toxicity multi-specific immunotherapies, showcasing the company's strategic advantage in innovative drug development.
- Industry Influence: With her previous executive roles, particularly at Anika Therapeutics, Dr. Blanchard is poised to enhance Xilio's market competitiveness and strategic direction, leveraging her extensive experience in the life sciences sector.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: On April 1, 2026, Xilio Therapeutics granted 3,257 non-qualified stock options to two new employees at an exercise price of $8.48 per share, equal to the closing price that day, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Vesting Arrangement: The stock options will vest 25% after the first year of employment, with the remaining 75% vesting in 36 equal monthly installments, ensuring continued employee contribution during their tenure with the company.
- Incentive Plan Context: This grant aligns with Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, designed to attract new employees in accordance with Nasdaq Listing Rule 5635(c)(4), thereby improving the overall talent quality within the company.
- Strategic Company Goals: Xilio Therapeutics focuses on developing immuno-oncology therapies without systemic side effects, leveraging proprietary masking technology to optimize anti-tumor activity, thereby enhancing treatment outcomes for cancer patients and showcasing the company's innovative potential in the biotechnology sector.
See More
XILIO THERAPEUTICS INC Reports Q4 Net Income of $10.36 Million
Company Overview: The article discusses the financial performance of a company named X, specifically focusing on its net income for the fourth quarter.
Financial Results: X reported a net income of USD 10.36 million for Q4, indicating a significant financial achievement for the period.
See More
XILIO THERAPEUTICS INC - FUNDING NOW SECURED UNTIL THE END OF 2027
Therapeutics in Cash Runway: The company has extended its cash runway through the end of 2027, indicating financial stability for ongoing projects.
Future Plans: This extension allows for continued investment in therapeutic development and potential new initiatives without immediate financial pressure.
See More
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
- Reverse Stock Split Plan: Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, aimed at increasing the per-share market price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Capital Adjustment Impact: The reverse split will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million, with trading expected to commence on a split-adjusted basis on March 16, 2026, enhancing per-share value to attract investors.
- Market Reaction: Following the reverse split announcement, XLO shares fell 16.48% in premarket trading to $0.451, indicating market concerns regarding the company's current stock price and future outlook, which may affect investor confidence.
- Compliance Objective: By implementing the reverse stock split, Xilio aims to restore compliance with Nasdaq, ensuring the company can continue trading in the public market and avoid delisting risks due to low stock prices.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Xilio Therapeutics granted 50,050 non-qualified stock options to two new employees, with an exercise price of $0.5283 per share, reflecting the company's proactive approach to talent acquisition.
- Option Structure: Each stock option has a ten-year term, with 25% of shares vesting after the first year and the remaining 75% vesting in 36 equal monthly installments, designed to incentivize long-term employee retention and enhance company stability.
- Incentive Plan Context: The stock options are granted under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4) to attract new talent, demonstrating the company's commitment to human resources.
- Strategic Company Goals: Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients, leveraging proprietary technology to advance novel therapeutic molecules, showcasing its innovative capabilities in the biotechnology sector.
See More
